ApostoliaMaria(Tsimperidou)TsimberidouMDPhD

Hematologic Oncology

Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,

Join to view full profile

Dr. Tsimberidou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tsimberidou's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

Aristotle University of Thessaloniki School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2010 - 2024
OK State Medical License 2020 - 2021

Clinical Trials

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis Start of enrollment: 2007 Jun 01
Completed
Phase 1
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin Start of enrollment: 2006 Jun 01
Completed
Phase 1
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement Start of enrollment: 2005 Mar 01
Completed
Phase 1
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement Start of enrollment: 2005 Oct 01
Completed
Phase 1
Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol Start of enrollment: 2009 Feb 01
Recruiting
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab Start of enrollment: 2009 Jul 01
Completed
Phase 1
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders Start of enrollment: 2013 May 01
Withdrawn
Phase 1
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Start of enrollment: 2009 Sep 01
Completed
Phase 1
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy Start of enrollment: 2009 Dec 01
Completed
Phase 1
HAI Abraxane With Gemcitabine and Bevacizumab Start of enrollment: 2010 Jan 01
Completed
Phase 1
Bendamustine and Bevacizumab for Advanced Cancers Start of enrollment: 2010 Jun 01
Completed
Phase 1
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) Start of enrollment: 2010 Aug 01
Completed
Phase 1
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Start of enrollment: 2010 Sep 30
Completed
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 13
Completed
Phase 1
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) Start of enrollment: 2014 May 13
Active, not recruiting
Not Applicable
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy Start of enrollment: 2014 Aug 01
Withdrawn
Phase 1
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. Start of enrollment: 2018 May 07
Terminated
Phase 1, Phase 2
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors Start of enrollment: 2018 Jun 07
Terminated
Phase 1, Phase 2
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors Start of enrollment: 2019 Dec 10
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care.
Apostolia M Tsimberidou, Anthony Sireci, Robert Dumanois, Daryl Pritchard> ;JCO Oncology Practice. 2024 Mar 5
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid M...
Subbiah, V., Coleman, N., Piha-Paul, S., Tsimberidou, A., Janku, F., Rodon, J., Pant, S., Dumbrava, E., Fu, S., Hong, D., Zhang, S., Sun, M., Jiang, Y., Roszik, J., So...> ;Cancer Research Communications. 2024 Feb 12
Autologous engineered T cell receptor therapy in advanced cancer.
Baysal, M., Chakraborty, A., Tsimberidou, A., Andersson, B.> ;Human Vaccines & Immunotherapeutics. 2023 Dec 15
1 citations
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.
Yannick Bulliard, Borje S Andersson, Mehmet A Baysal, Jason Damiano, Apostolia M Tsimberidou> ;Journal of Hematology & Oncology. 2023 Oct 25
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Anne Knisely, Jibran Ahmed, Bettzy Stephen, Sarina A Piha-Paul, Daniel Karp, Abdulrazzak Zarifa, Siqing Fu, David Sanghyun Hong, Jordi Rodon Ahnert, Timothy A Yap, Apo...> ;Cancer. 2024 Feb 1
3 citations
Molecular tumour boards - current and future considerations for precision oncology.
Apostolia M Tsimberidou, Michael Kahle, Henry Hiep Vo, Mehmet A Baysal, Amber Johnson, Funda Meric-Bernstam> ;Nature Reviews. Clinical Oncology. 2023 Dec 1
6 citations
Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Christina M Lockwood, Laetitia Borsu, Milena Cankovic, Jonathan S L Earle, Christopher D Gocke, Meera Hameed, Danielle Jordan, Jean R Lopategui, Mrudula Pullambhatla, ...> ;The Journal of Molecular Diagnostics. 2023 Dec 1
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
Anca Chelariu-Raicu, Sarina A Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M Tsi...> ;Journal of Immunotherapy and Precision Oncology. 2023 Aug 1
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 ...
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D Kawedia, Siqing Fu, Shubham Pant, Timothy A ...> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K Sood, Jordi Rodon, Daniel D Karp, George Blumenschein, Scott Kopetz, Shu...> ;The Oncologist. 2023 Dec 11
Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors.
Apostolia Maria Tsimberidou, Claire F Verschraegen, Robert Wesolowski, Chi-Sheng Shia, Pei Hsu, Tillman E Pearce> ;British Journal of Cancer. 2023 Aug 1
5 citations
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Apostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sab...> ;Cancer Immunology Research. 2023 Jul 5
1 citations
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Shizhen Zhang, Apostolia M Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A Yap, David S Hong, M...> ;NPJ Precision Oncology. 2023 Apr 18
2 citations
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, Shiraj Sen, David S Hong, Aung Naing, Cynthia E Herzog, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon, Timothy ...> ;Clinical Cancer Research. 2023 May 1
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Deby Ogbonna, Daniel D Karp, Ecaterina Dumb...> ;Cancer. 2023 Jul 15
5 citations
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer WithAmplification, Overexpression, or Mutation: Results From the TAPUR Study.
Eugene R Ahn, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Hussein M Ali-Ahmad, John Chan, Michael L Maitland, Sapna R Patel, Zachary Reese, Ani S Balmanoukia...> ;JCO Precision Oncology. 2023 Apr 1
5 citations
Precision Oncology: Evolving Clinical Trials across Tumor Types.
I-Wen Song, Henry Hiep Vo, Ying-Shiuan Chen, Mehmet A Baysal, Michael Kahle, Amber Johnson, Apostolia M Tsimberidou> ;Cancers. 2023 Mar 25
3 citations
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa...> ;NPJ Precision Oncology. 2023 Feb 18
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
Son, J., Lin, H., Fu, S., Biter, A., Dumbrava, E., Karp, D., Naing, A., Pant, S., Piha-Paul, S., Rodon, J., Subbiah, V., Tsimberidou, A., Yap, T., Frumovitz, M., Jazae...> ;Journal of Immunotherapy and Precision Oncology. 2023 Feb 1
68 citations
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Timothy A Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop M Kantarjian, Farhad Ravandi, Meghan E Collins, Maria ...> ;Nature Medicine. 2023 Jan 1
1 citations
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.
Apostolia Maria Tsimberidou, Henry Hiep Vo, Jennifer Beck, Chi-Sheng Shia, Pei Hsu, Tillman E Pearce> ;JCO Precision Oncology. 2023 Jan 1
3 citations
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expans...
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, Sarina Piha-Paul, Fechukwu Akhmedzhanov, Bulent Yilmaz, Lacey McQuinn, Amanda L Brink, Jing Gong, Cheuk Hong Leung,...> ;Gynecologic Oncology. 2023 Jan 1
6 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Henry Hiep Vo, Siqing Fu, David S Hong, Daniel D Karp, Sarina Piha-Paul, Vivek Subbiah, Filip Janku, Aung Naing, Timothy A Yap, Jordi Rodon, Jaffer A Ajani, Carrie Car...> ;NPJ Precision Oncology. 2022 Oct 27
60 citations
Clinical trial design in the era of precision medicine.
Elena Fountzilas, Apostolia M Tsimberidou, Henry Hiep Vo, Razelle Kurzrock> ;Genome Medicine. 2022 Aug 31
1 citations
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Tito R Mendoza, David S Hong, Christine B Peterson, Bettzy Stephen, Ecaterina Dumbrava, Shubbam Pant, Apostolia Maria Tsimberidou, Timothy Anthony Yap, Ajay Sheshadri,...> ;Scientific Reports. 2022 Aug 23
Join now to see all

Journal Articles

A Nonparametric Bayesian Basket Trial Design
Apostolia (Tsimperidou) Tsimberidou, MD, Biometrical Journal

Lectures

Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period at The IMPACT study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Issue HighlightsAugust 24th, 2020
Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid CancersMarch 19th, 2019
Nature Publication Reports First-in-Human Trial for a Personalized Cancer ImmunotherapyDecember 20th, 2018
Join now to see all

Hospital Affiliations

University of Texas M.D. Anderson Cancer CenterHouston, Texas